Key Quantitative Figures
Standalone Financial Results (Quarter Ended September 30, 2026):
- Revenue from operations: ₹235.13 crore
- Other income: ₹(2.31) crore (negative)
- Total income: ₹232.82 crore
- Profit before tax: ₹49.24 crore
- Tax expense: ₹12.90 crore
- Profit for the quarter: ₹36.34 crore
- Earnings per share (basic and diluted): ₹2.92
Standalone Financial Results (Half Year Ended September 30, 2026):
- Revenue from operations: ₹459.53 crore
- Other income: ₹11.70 crore
- Total income: ₹471.24 crore
- Profit before tax: ₹136.58 crore
- Tax expense: ₹37.21 crore
- Profit for the period: ₹99.37 crore
- Earnings per share (basic and diluted): ₹8.21
Consolidated Financial Results (Quarter Ended September 30, 2026):
- Revenue from operations: ₹235.13 crore
- Other income: ₹(1.94) crore (negative)
- Total income: ₹233.19 crore
- Profit before tax: ₹49.53 crore
- Tax expense: ₹12.90 crore
- Profit for the quarter: ₹36.63 crore
- Earnings per share (basic): ₹2.95; (diluted): ₹2.94
Consolidated Financial Results (Half Year Ended September 30, 2026):
- Revenue from operations: ₹459.53 crore
- Other income: ₹25.13 crore
- Total income: ₹484.66 crore
- Profit before tax: ₹137.06 crore
- Tax expense: ₹37.22 crore
- Profit for the period: ₹99.84 crore
- Earnings per share (basic): ₹8.21; (diluted): ₹8.19
Segment-wise Performance (Half Year Ended September 30, 2026):
- Ayurvedic products/medicines: Revenue ₹262.17 crore, Result ₹70.83 crore
- Ayurvedic healthcare services: Revenue ₹194.58 crore, Result ₹76.48 crore
- Others: Revenue ₹2.78 crore, Result ₹2.78 crore
Balance Sheet Highlights (Standalone as of September 30, 2026):
- Total assets: ₹826.69 crore
- Total equity: ₹517.08 crore
- Paid-up equity share capital: ₹24.86 crore (Face value ₹2 each)
- Other equity: ₹492.22 crore
Subsequent Events:
1. The company incorporated Ayugenomics Private Limited as a subsidiary on November 11, 2026. The company subscribed to 30,000 equity shares of ₹10 each, aggregating to ₹3.00 lakh, representing 60% of the equity share capital.
2. The Nomination and Remuneration Committee approved allotment of 23,374 equity shares of face value ₹2 each to eligible employees pursuant to ESOP scheme on October 10, 2026. Paid-up equity share capital increased from ₹24,86,01,460 to ₹24,86,48,208.
3. The company exercised conversion rights for 4.5 lakh convertible warrants allotted by Chandan Healthcare Limited and remitted balance 75% consideration amounting to ₹789.75 lakh. Allotment pending stock exchange approval.
4. Shareholders approved final dividend of ₹4.50 per equity share at AGM held on September 28, 2026.
Operational Highlights:
- The company sold land and building constituting its Derabassi hospital facility during the quarter and took back the premises on lease to ensure continued operations.
Financial Statement Details:
The financial results include complete balance sheets, profit and loss statements, cash flow statements, and segment reporting for both standalone and consolidated entities, prepared in accordance with Ind AS 34.